Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1974 2
1975 1
1978 1
1994 1
1995 1
1996 1
1999 1
2001 1
2002 1
2009 1
2019 2
2020 6
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters.
Xu C, Rafique A, Potocky T, Paccaly A, Nolain P, Lu Q, Iglesias-Rodriguez M, St John G, Nivens MC, Kanamaluru V, Fairhurst J, Ishii T, Maldonado R, Choy E, Emery P. Xu C, et al. Among authors: st john g. J Clin Pharmacol. 2021 May;61(5):714-724. doi: 10.1002/jcph.1795. Epub 2021 Jan 26. J Clin Pharmacol. 2021. PMID: 33314148 Free article.
Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng et al.
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Pappas DA, et al. Among authors: st john g. Ann Rheum Dis. 2022 Nov;81(11):e225. doi: 10.1136/annrheumdis-2020-218907. Epub 2020 Nov 11. Ann Rheum Dis. 2022. PMID: 33177102 No abstract available.
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry.
Curtis JR, Weinblatt M, Saag K, Bykerk VP, Furst DE, Fiore S, St John G, Kimura T, Zheng S, Bingham CO 3rd, Wright G, Bergman M, Nola K, Charles-Schoeman C, Shadick N. Curtis JR, et al. Among authors: st john g. Arthritis Care Res (Hoboken). 2021 Apr;73(4):471-480. doi: 10.1002/acr.24471. Epub 2021 Mar 13. Arthritis Care Res (Hoboken). 2021. PMID: 33002337 Free PMC article.
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Pappas DA, et al. Among authors: st john g. Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21. Ann Rheum Dis. 2021. PMID: 32719038 Free PMC article.
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis.
Kovalenko P, Paccaly A, Boyapati A, Xu C, St John G, Nivens MC, Davis JD, Rippley R, DiCioccio AT. Kovalenko P, et al. Among authors: st john g. CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):405-416. doi: 10.1002/psp4.12534. Epub 2020 Jun 20. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32453485 Free PMC article.
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC. Burmester GR, et al. Among authors: st john g. RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019. RMD Open. 2019. PMID: 31673415 Free PMC article. Clinical Trial.
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR. Genovese MC, et al. Among authors: st john g. Arthritis Res Ther. 2020 Jun 10;22(1):139. doi: 10.1186/s13075-020-02194-z. Arthritis Res Ther. 2020. PMID: 32522251 Free PMC article. Clinical Trial.
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gómez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR. Genovese MC, et al. Among authors: st john g. RMD Open. 2019 Aug 1;5(2):e000887. doi: 10.1136/rmdopen-2018-000887. eCollection 2019. RMD Open. 2019. PMID: 31452928 Free PMC article. Clinical Trial.
23 results